Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
26 hedge funds and large institutions have $909K invested in Titan Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 26 → 26 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
53% less capital invested
Capital invested by funds: $1.94M → $909K (-$1.03M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$545K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$76.2K |
| 3 |
VF
Virtu Financial
New York
|
+$62.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$25.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$1M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$314K |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$204K |
| 4 |
Renaissance Technologies
New York
|
-$139K |
| 5 |
AC
Armistice Capital
New York
|
-$46K |
TTNP Hedge Fund Activity: Q4 2018 in Review
26 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2018, worth a combined $909K — down 53% from $1.94M a quarter earlier.
Fund positioning in TTNP was balanced in Q4 2018: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $545K. The largest seller was Cornerstone Wealth Management, exiting entirely with an estimated $1M sold.
- 26 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $909K of Titan Pharmaceuticals stock for Q4 2018, down 53% quarter-over-quarter.
- 5 funds opened new Titan Pharmaceuticals positions in Q4 2018 and 5 closed out, a net change of 0 holders.
- The largest Titan Pharmaceuticals buyer in Q4 2018 was Vanguard Group, an estimated $545K added.
- The largest Titan Pharmaceuticals seller in Q4 2018 was Cornerstone Wealth Management, an estimated $1M sold.
Based on aggregated 13F filings for Q4 2018.